Newbury Pharmaceuticals

Prenumeration

Kalender

	Tid*
2025-01-16	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15	-	Årsstämma
2025-01-15	-	Kvartalsrapport 2025-Q1
2024-10-23	-	Bokslutskommuniké 2024
2024-07-31	-	Extra Bolagsstämma 2024
2024-07-10	-	Kvartalsrapport 2024-Q3
2024-04-10	-	Kvartalsrapport 2024-Q2
2024-01-11	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10	-	Årsstämma
2024-01-10	-	Kvartalsrapport 2024-Q1
2023-10-11	-	Bokslutskommuniké 2023
2023-07-14	-	Kvartalsrapport 2023-Q3
2023-04-12	-	Kvartalsrapport 2023-Q2
2023-01-12	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11	-	Årsstämma
2023-01-11	-	Kvartalsrapport 2023-Q1
2022-10-13	-	Bokslutskommuniké 2022
2022-07-06	-	Kvartalsrapport 2022-Q3
2022-04-13	-	Kvartalsrapport 2022-Q2

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Läkemedel & Handel

Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.

Filter

År

Typ

Språk

Rensa

2024-10-28 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Buspiron 4,00 SEK | +3,09% | 0,40 MSEK

2024-10-23 11:15:00 Newbury Pharmaceuticals year-end report September 2023 – August 2024 3,78 SEK | -4,55% | 0,34 MSEK

2024-09-30 09:00:00 Newbury Pharmaceuticals AB has agreed to extend the existing 15 MSEK loan agreement. 3,78 SEK | +3,28% | 0,22 MSEK

2024-09-27 15:56:00 Strong Quarterly Sales Announcement from Newbury Pharmaceuticals 3,66 SEK | +10,91% | 0,33 MSEK

2024-09-23 13:00:00 Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden 3,18 SEK | +5,30% | 0,24 MSEK

2024-09-13 11:30:00 Regulatory Filing for Teduglutide 3,26 SEK | +5,16% | 0,25 MSEK

2024-07-31 10:04:00 Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) 3,70 SEK | +5,11% | 0,11 MSEK

2024-07-12 09:30:00 NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEWBURY PHARMACEUTICALS AB 3,30 SEK | -2,37% | 0,01 MSEK

2024-07-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – May 2024 3,26 SEK | -6,86% | 0,14 MSEK

2024-06-20 13:00:00 Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen 3,46 SEK | +8,81% | 0,18 MSEK

2024-06-18 08:45:00 Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder 3,28 SEK | +1,86% | 0,04 MSEK

2024-04-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – February 2024 3,41 SEK | -2,29% | 0,13 MSEK

2024-03-04 08:15:00 Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million 4,39 SEK | -0,90% | 0,18 MSEK

2024-02-22 08:30:00 Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK 4,39 SEK | +2,33% | 0,01 MSEK

2024-01-17 10:00:00 Nintedanib Newbury approved by the Swedish Health Authorities 3,75 SEK | +1,63% | 0,09 MSEK

2024-01-10 11:20:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 3,67 SEK | +16,51% | 0,61 MSEK

2024-01-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – November 2023 3,67 SEK | +16,51% | 0,61 MSEK

2023-12-13 23:00:00 Newbury Pharmaceuticals publishes its annual report for 2022/2023 3,79 SEK | +1,88% | 0,12 MSEK

2023-12-08 13:00:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 3,64 SEK | +3,41% | 0,04 MSEK

2023-10-20 08:00:00 Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg 3,03 SEK | -0,66% | 0,00 MSEK

2023-10-11 08:00:00 Newbury Pharmaceuticals year-end report September 2022 – August 2023 3,32 SEK | +1,53% | 0,09 MSEK

2023-10-06 13:00:00 Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products. 3,15 SEK | +3,62% | 0,15 MSEK

2023-09-22 10:00:00 Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide 3,91 SEK | +3,71% | 0,05 MSEK

2023-09-18 14:00:00 Newbury Pharmaceuticals AB has successfully signed a 15 MSEK loan agreement 3,91 SEK | +1,56% | 0,11 MSEK

2023-08-23 08:00:00 Newbury gains access to the Nordic hospital market with a new strategic partnership for prescription medicine 3,95 SEK | 0,00% | 0,10 MSEK

2023-07-19 11:30:00 Desmopressin Newbury approved by the Swedish Health Authorities 3,23 SEK | +5,90% | 0,22 MSEK

2023-06-16 09:42:00 Newbury Pharmaceuticals sets financial goals for 2024 and 2028 4,08 SEK | -0,49% | 0,11 MSEK

2023-06-14 08:00:00 Newbury Pharmaceuticals interim report September 2022 – May 2023 3,57 SEK | +0,56% | 0,40 MSEK

2023-06-13 17:40:00 Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14 3,57 SEK | +0,56% | 0,40 MSEK

2023-05-25 13:00:00 Newbury to present at Redeye Growth Day 2023 5,22 SEK | -3,33% | 0,09 MSEK

2023-05-12 08:30:00 Pirfenidone Newbury approved by the Norwegian Health Authorities 5,48 SEK | +1,48% | 0,03 MSEK

2023-05-02 11:00:00 Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities 5,56 SEK | -2,46% | 0,30 MSEK

2023-04-12 08:00:00 Newbury Pharmaceuticals interim report September 2022 – February 2023 5,68 SEK | -12,88% | 0,95 MSEK

2023-03-24 11:45:00 Lapatinib Newbury approved by the Swedish Health Authorities 6,13 SEK | +6,07% | 0,62 MSEK

2023-03-06 14:30:00 Dimethyl Fumarate Newbury approved by the Swedish Health Authorities 6,00 SEK | -3,23% | 0,15 MSEK

2023-02-02 07:45:00 Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets 5,95 SEK | +2,87% | 0,10 MSEK

2023-01-11 11:45:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 6,16 SEK | -12,00% | 1,07 MSEK

2023-01-11 08:00:00 Newbury Pharmaceuticals interim report September 2022 – November 2022 6,16 SEK | -12,00% | 1,07 MSEK

2023-01-09 08:00:00 International sales orders for 2023 7,00 SEK | -6,05% | 0,33 MSEK

2022-12-27 10:00:00 Fampridine Newbury approved by the Swedish Health Authorities 6,85 SEK | +0,75% | 0,12 MSEK

2022-12-14 08:00:00 Newbury Pharmaceuticals publishes its annual report for 2021/2022 6,91 SEK | -1,27% | 0,05 MSEK

2022-12-08 12:00:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 6,93 SEK | -1,27% | 0,07 MSEK

2022-12-06 07:00:00 Redeye will host two events with Newbury Pharmaceuticals in December 7,00 SEK | +4,43% | 0,24 MSEK

2022-11-23 09:30:00 Newbury expands its portfolio with two ready to launch products 7,14 SEK | -1,82% | 0,20 MSEK

2022-11-22 08:00:00 Newbury will participate at the RedEye Life Science Day – 24th November 2022 7,27 SEK | -0,93% | 0,05 MSEK

2022-11-01 08:30:00 Teriflunomide Newbury approved by the Norwegian Health Authorities 5,51 SEK | +5,15% | 0,14 MSEK

2022-10-13 08:00:00 Newbury Pharmaceuticals year-end report September 2021 – August 2022 4,36 SEK | +4,31% | 0,23 MSEK

2022-09-07 13:15:00 Newbury Pharmaceuticals management has purchased shares in the company 4,09 SEK | +2,26% | 0,56 MSEK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Newbury Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden